0.0000 (0.0000%)
  • Bid / Lots
    5.3000/ 1
  • Ask / Lots
    6.0100/ 39
  • Open / Previous Close
    5.5500 / 5.7900
  • Day Range
    Low 5.4102
    High 5.9500
  • 52 Week Range
    Low 3.4200
    High 19.7200
  • Volume
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 5.39
09:36 ET12885.55
09:38 ET15005.53
09:54 ET11865.6783
10:01 ET14855.7
10:03 ET1005.74
10:10 ET5765.87
10:17 ET76005.795
10:19 ET16655.78
10:21 ET8005.79
10:26 ET3715.76
10:30 ET1005.76
10:32 ET1005.76
10:37 ET1505.6562
10:42 ET1005.76
11:00 ET21305.7
11:02 ET3005.675
11:06 ET4955.7
11:09 ET56005.65
11:11 ET73645.59
11:15 ET1005.59
11:22 ET82475.47
11:24 ET1005.47
11:26 ET1005.47
11:38 ET3005.47
11:40 ET447635.6
11:58 ET1005.53
01:30 ET1005.73
01:53 ET10005.8809
02:00 ET4005.85
02:11 ET1005.79
02:20 ET1005.94
02:29 ET1005.93
02:31 ET7265.908
02:40 ET1005.9
02:44 ET2505.9016
02:47 ET2005.93
02:54 ET10115.8375
03:02 ET5005.94
03:05 ET1005.94
03:12 ET2005.94
03:39 ET1465.88
03:41 ET2005.92
03:48 ET1005.86
03:52 ET1005.885
03:54 ET20865.8108
03:56 ET42885.87
03:57 ET15005.805
03:59 ET72565.79
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesHOWL
Werewolf Therapeutics Inc
United StatesIMUX
Immunic Inc
United StatesTFFP
TFF Pharmaceuticals Inc
United StatesPRTG
Portage Biotech Inc
United StatesCELC
Celcuity Inc
United StatesENZC
Enzolytics Inc
As of 2022-08-08

Company Information

Werewolf Therapeutics, Inc. is a biopharmaceutical company focused on developing a pipeline of cancer treatments. The Company is developing immuno-stimulatory therapeutics designed to act selectively within the tumor microenvironment to enhance the body’s immune response to cancer. The Company’s product candidates include WTX-124, WTX-330 and WTX-613. The Company’s advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12). Its INDUKINE molecules for the treatment of solid tumors. The Company initiating a Phase I/Ib clinical trial for each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. WTX-613 is designed to have minimal activity in the periphery and is activated preferentially in the tumor microenvironment (TME) to release wild-type IFNα in the tumor and potentially stimulate an anti-tumor immune response.

Contact Information

200 Talcott Avenue, 2Nd FloorWATERTOWN, MA, United States 02472


Independent Chairman of the Board
Luke Evnin
President, Chief Executive Officer, Director
Daniel Hicklin
Chief Financial Officer, Treasurer
Timothy Trost
Chief Operating Officer
Reid Leonard
Chief Technology Officer
Chulani Karunatilake

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.